Japanese conglomerate Asahi Kasei agreed an all‑cash acquisition of German antiviral specialist Aicuris for roughly €780 million (about $920 million). The purchase brings marketed product Prevymis (letermovir) and late‑stage candidate pritelivir, alongside antisense program AIC‑468 for BK virus. Asahi Kasei signalled the deal will expand its infectious‑disease offerings for immunocompromised patients and accelerate R&D Aicuris has reported strong sales and clinical progress for its pipeline; the acquisition will close pending regulatory approvals expected in the first half of 2026. Asahi Kasei concurrently announced licensing collaborations to combine internal development capabilities with Alchemedicine’s discovery platform, extending its discovery engine. Company statements and independent coverage noted this move as part of a broader consolidation in antivirals and transplant‑focused therapeutics.